Tumor Immunology

Tumor immunology is the study of how the immune system recognizes, attacks, ignores, or is co-opted by cancer.

16 frameworks, from 1891 to today · Immunology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Tumor immunology is the study of how the immune system recognizes, attacks, ignores, or is co-opted by cancer1. Its central stakes are practical and urgent: if the immune system can be made to kill tumor cells selectively and remember them, cancer becomes a disease that can be controlled without the collateral damage of surgery, radiation, and chemotherapy. At the same time, tumors are derived from the body's own cells, so the field's governing problem is a discrimination problem—how a self-derived growth can be distinguished from healthy tissue, and why the immune system so often fails to do so. The history of the field is the story of how successive generations of researchers built methods to see immune-tumor interactions, argued over whether those interactions mattered, and eventually turned them into some of the most effective cancer treatments in use.

From Coley's Toxins to the Immune Surveillance Hypothesis

In the 1890s, the New York surgeon William Coley observed that some patients whose tumors regressed had suffered severe bacterial infections, and he began injecting killed bacteria—"Coley's toxins"—into tumors, reporting occasional dramatic regressions. The approach was inconsistent and poorly understood, and with the rise of radiation therapy and chemotherapy it fell out of mainstream oncology. But it established a durable intuition: if the immune system can be roused against tumor tissue, tumors can melt away.

For much of the twentieth century, the dominant model was humoral: immunity against tumors, where it was believed to exist, was thought to depend on antibodies. That began to change as cellular immunology matured around the middle of the century. The demonstration that lymphocytes could kill target cells in culture, and that T cells recognize antigen only when it is presented on the surface of a cell in the context of molecules encoded by the major histocompatibility complex (MHC)—a finding established through work on transplantation and on virus-infected cells—gave investigators the conceptual tools to ask whether T cells could see tumors. The discovery of tumor-specific transplantation antigens in inbred mice, notably by George Klein and colleagues in the 1960s, showed that chemically induced and virus-induced tumors could be rejected by a previously sensitized host—the founding evidence for a tumor antigen paradigm.

These results were read as support for a broader theory. In 1957, Lewis Thomas argued that the primary biological function of cellular immunity was to police the body for mutant cells; Macfarlane Burnet developed the idea into what became known as immune surveillance—the proposition that the immune system continuously eliminates nascent tumors. The idea was elegant and influential, but by the 1970s it ran into trouble: immunodeficient mice did not, on the whole, show dramatically increased rates of spontaneous tumors, and the theory was declared moribund by several reviewers. The field's attention shifted to the mechanisms by which tumors evade immunity.

Escape, Suppression, and the Tumor Microenvironment

The recognition that tumors are not passive targets gave rise to the study of tumor escape and immunosuppression. Building on Peter Medawar's and others' work on why transplants are rejected, investigators in the 1950s and 1960s established that antigenically foreign tissues are attacked by cellular effector mechanisms—an early demonstration that lymphocytes, not just antibodies, could act as cellular effector immunology against tissue. Transplant immunologists then turned the lens on tumors: a tumor, like a graft, must overcome the same effector machinery.

Work through the 1970s and 1980s identified several mechanisms of escape. Tumors were found to lose expression of MHC molecules, masking themselves from T-cell recognition; they were found to produce factors that blunt immune responses; and they were found to be surrounded by a cellular environment—later called the tumor microenvironment—that includes suppressive cells1. The identification of regulatory T cells as a distinct lineage in the 1990s, especially through the work of Shimon Sakaguchi, gave the field a canonical suppressor arm. So did myeloid-derived suppressor cells, described as a coherent category in the early 2000s. The realization that a tumor's physical environment—hypoxia, stromal cells, extracellular matrix, chemokines—shapes immune behavior drove the emergence of tumor microenvironment analysis as a method-driven field, using flow cytometry, immunohistochemistry, and later single-cell profiling to map who is present in a tumor and what is doing what.

The escape literature had a deep conceptual consequence: immunity against cancer exists but is often subverted. In 2002, Robert Schreiber, Lloyd Old, and colleagues reformulated immune surveillance as cancer immunoediting—a three-phase process of elimination, equilibrium, and escape, in which tumors are sculpted by immune pressure. Their studies of mice with disabled immune effector pathways showed that sarcomas arising in immunodeficient hosts were more immunogenic than those in intact hosts—evidence that the immune system had been editing tumors by killing the most recognizable ones.

Antigens, Vaccines, and the Road to Rational Design

To make immunotherapy precise, researchers needed to know what the immune system sees on tumors. The discovery of tumor antigens proceeded in generations: transplantation antigens in mice (1960s); oncofetal antigens such as carcinoembryonic antigen and alpha-fetoprotein (1960s–70s); and, from the 1980s, molecularly defined antigens. The decisive step came when Thierry Boon and colleagues at the Ludwig Institute in Brussels used T-cell clones to identify the first human tumor antigen gene, MAGE-1, in 1991, by cloning the DNA that conferred recognition by tumor-specific cytotoxic T cells. This made the tumor antigen paradigm tangible at a molecular level: antigens were mutated or aberrantly expressed self-peptides presented by MHC, and could be tested as vaccines.

Cancer vaccination attempts followed rapidly, including dendritic cell vaccines (the first therapeutic cancer vaccine, sipuleucel-T, was approved in 2010 for prostate cancer, based on antigen-pulsed dendritic cells) and trials of peptide vaccines. Most early trials showed immunological responses but disappointing clinical benefit, teaching the field that generating immunity is only the first step—the induced T cells must traffic to and function within a suppressive microenvironment. The tumor antigen paradigm also brought a key distinction, between mutation-derived neoantigens—which are truly foreign—and self-antigens, which the immune system has been selected to tolerate2.

Antibodies and Cell Therapies

In parallel with T-cell work, antibody-based therapy developed its own lineage. The hybridoma method of Georges Köhler and César Milstein in 1975 made monoclonal antibodies possible, allowing researchers to manufacture a single antibody species against a chosen target3. Initial trials with mouse antibodies were stymied by human anti-mouse responses; chimeric and then fully humanized antibodies solved this, and monoclonal antibody therapeutics became a pillar of cancer treatment. Trastuzumab, approved in 1998, targeted HER2-positive breast cancer; rituximab targeted CD20 on B-cell lymphomas. Antibody drugs act through several routes—blocking growth signals, delivering cytotoxic payloads, or engaging immune effector cells through their Fc regions.

Cellular therapy pursued a different route. Early adoptive cell therapy experiments in the 1980s, notably by Steven Rosenberg at the National Cancer Institute, used lymphokine-activated killer cells and later tumor-infiltrating lymphocytes (T cells isolated from a patient's own tumor, expanded in culture, and reinfused) to produce occasional durable regressions in melanoma. The approach worked only in a subset of patients and was technically demanding, but it proved that a patient's own T cells could be reinforced to attack their cancer.

The most radical step in this line of work was the engineering of the T-cell receptor itself. Chimeric antigen receptors (CARs)—synthetic molecules that combine an antibody-derived targeting domain with intracellular signaling domains—were first described by Zelig Eshhar and colleagues in the late 1980s; the "T-body" design allowed a T cell to recognize a surface antigen directly without MHC presentation. Second-generation CARs, adding a co-stimulatory domain (such as CD28 or 4-1BB), were developed in the late 1990s and early 2000s by the groups of Michel Sadelain, Carl June, and others, and proved crucial for CAR T cells to persist and function. In 2017, the first CAR T-cell therapy, tisagenlecleucel (Kymriah), was approved for a form of pediatric leukemia, followed by axicabtagene ciloleucel (Yescarta) for lymphoma—landmark approvals that turned cellular engineering into a clinical discipline, and CAR T-cell engineering into a mature technology with its own complications to manage, such as cytokine release syndrome.

Checkpoint Blockade and the Integration of the Field

The single event that transformed tumor immunology from a field of promise into standard-of-care medicine was the clinical validation of immune checkpoint blockade. The concept came from fundamental immunology: CTLA-4 (identified by Pierre Golstein's group in 1987 as a molecule on activated T cells) was shown by James Allison and colleagues in the mid-1990s to act as a negative regulator of T-cell activation; blocking CTLA-4 with an antibody could unleash anti-tumor T cells in mice and cause tumor rejection. This was a deliberate, theory-driven demonstration that releasing the brakes on T cells—not accelerating them—could control tumors. Clinical trials of ipilimumab, an anti-CTLA-4 antibody, produced the first randomized evidence of a survival benefit in metastatic melanoma in 2010, and it was approved in 2011.

A second checkpoint, PD-1, was identified in the early 1990s by Tasuku Honjo's group, with its ligands PD-L1 and PD-L2 characterized later. Early clinical trials of anti-PD-1 and anti-PD-L1 antibodies, reported around 2012–2014, showed striking responses in melanoma, lung cancer, and other tumors; pembrolizumab and nivolumab were approved in 2014. The logic of checkpoint blockade is a kind of negative-space logic: the immune system already has T cells that recognize tumors, but they are held in check by inhibitory signals—often signals that tumors themselves exploit by expressing PD-L1. Blocking the signal restores the response. This reframed the entire field around the idea that the main obstacle to cancer immunity is regulation rather than recognition.

Checkpoint blockade also created urgent practical questions that drove the next phase of work. No single therapy worked for most patients; combining checkpoints with each other, with vaccines, with chemotherapy, radiation, and adoptive cell therapy became a major research program. Predicting who would respond required predictive biomarkers, and the search for valid ones centered on tumor PD-L1 expression, tumor mutational burden—the number of mutations per tumor, a rough proxy for neoantigen load—and immune infiltration patterns. Microsatellite instability emerged as a powerful predictor; in 2017, the FDA approved pembrolizumab for any solid tumor with mismatch-repair deficiency or high microsatellite instability, the first tissue-agnostic cancer approval. T-cell inflamed gene expression profiles and multiplex immunohistochemistry entered routine use in research, while questions of primary and acquired resistance became central.

Oncolytic virotherapy returned to the older intuition—a virus can inflame a tumor and break tolerance—through engineered viruses designed to replicate selectively in tumor cells and to stimulate immunity. The first approved agent, talimogene laherparepvec (T-VEC), was approved in 2015 for melanoma, though the strategy remains an active experimental area rather than a central pillar. More recently, the immunology of tumors has been integrated with the recognition that the tumor microenvironment is a dynamic, spatially organized system, studied with single-cell RNA sequencing and spatial transcriptomics; and that tumors vary in their "immune phenotypes"—hot, inflamed tumors respond to checkpoint blockade, cold tumors often do not—a distinction that now organizes combination strategy design.

Where the Subject Stands

Today tumor immunology operates on several converging fronts: checkpoint blockade and its combinations, CAR T-cell therapy and other engineered cell therapies (including tumor-infiltrating lymphocyte therapy and T-cell receptor-engineered cells), therapeutic antibodies, cancer vaccines (particularly neoantigen-based), and oncolytic virotherapy14. The intellectual inheritance is visible in each—the tumor antigen paradigm supplies the targets, the escape literature supplies the barriers, and the surveillance framework supplies the rationale for intervening. What remains genuinely open is the problem that has shadowed the field since Coley: why some patients respond dramatically and most do not. Predictive biomarkers are still imperfect; the mechanisms by which tumors become resistant to immune attack are only partly mapped; and the tumor microenvironment's heterogeneity, and how to remodel it, remains a central question. The history shows the field's pattern clearly: each advance was made by building a method to see immune-tumor interactions more precisely, and then using clinical evidence to test whether the theory's predictions about which patients would benefit actually held.

References

  1. Cancer immunology (introduction, Definition, Tumor evasion mechanisms, Tumor microenvironment, Immunomodulation methods), Wikipedia
  2. Antigen (Neoantigens), Wikipedia
  3. Monoclonal antibody (History), Wikipedia
  4. Cellular adoptive immunotherapy, Wikipedia

The frameworks of Tumor Immunology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1891-1930

    Coley's Toxins

    Can infections provoke tumors to shrink?

    Fly to its tower in Nousfarer

  2. 1900-1960

    Humoral Tumor Immunity

    Do antibodies defend against cancer?

    Fly to its tower in Nousfarer

  3. 1957-1975

    Immune Surveillance

    Does immunity prevent tumors from forming?

    Fly to its tower in Nousfarer

  4. 1957-Present
  5. 1960-Present

    Tumor antigen

    What do immune cells see on tumors?

    Fly to its tower in Nousfarer

  6. 1970-Present
  7. 1970-Present

    Tumor Escape and Immunosuppression

    Why does the immune system fail against tumors?

    Fly to its tower in Nousfarer

  8. 1975-Present

    Monoclonal antibody therapy

    Can manufactured antibodies treat cancer?

    Fly to its tower in Nousfarer

  9. 1985-Present

    Adoptive cell transfer

    Can a patient's own cells be used as therapy?

    Fly to its tower in Nousfarer

  10. 1989-Present

    CAR T cell

    Can T cells be engineered to kill cancer?

    Fly to its tower in Nousfarer

  11. 1990-Present

    Cancer vaccine

    Can vaccines train immunity against tumors?

    Fly to its tower in Nousfarer

  12. 1990-Present

    Oncolytic virus

    Can viruses be used to attack tumors?

    Fly to its tower in Nousfarer

  13. 1990-Present

    Tumor microenvironment

    How does the tumor's surroundings affect immunity?

    Fly to its tower in Nousfarer

  14. 1996-Present

    Checkpoint inhibitor

    Can we release the brakes on immune attack?

    Fly to its tower in Nousfarer

  15. 2002-Present

    Immunoediting

    How does immunity sculpt tumor evolution?

    Fly to its tower in Nousfarer

  16. 2010-Present

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Coley's ToxinsHumoral Tumor ImmunityImmune SurveillanceImmunosurveillance and Cancer Immunoe…Tumor antigenCellular Effector Immunology of TumorsTumor Escape and ImmunosuppressionMonoclonal antibody therapyAdoptive cell transferCAR T cellCancer vaccineOncolytic virusTumor microenvironmentCheckpoint inhibitorImmunoeditingPredictive Immuno-Oncology Biomarkers

Beyond the field

Where Tumor Immunology's ideas came from in other fields, and what they led to there: the strongest 12 of 79 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Tumor Immunology is a planet in Nousfarer

Its city has a tower for each of these 16 frameworks. Land, walk in, and climb one concept at a time.

Land on Tumor Immunology

Related fields

Fields its ideas are linked to

More in Immunology

See where Tumor Immunology sits on the Map of Human Knowledge